U.S. FDA declines to approve Supernus’ drug-device combination for Parkinson’s disease

By Thomson Reuters Apr 8, 2024 | 8:38 AM

(Reuters) – The U.S. Food and Drug Administration (FDA) declined to approve Supernus Pharmaceuticals’ drug-device combination to treat movement-related symptoms of Parkinson’s disease, the drugmaker said on Monday.

(Reporting by Puyaan Singh in Bengaluru; Editing by Shinjini Ganguli)